rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Prothena Corporation plc -

PRTA · Nasdaq

Health CareBiotechnologyNot moving yet

PRTA stood above a rising 150-day average in 18 of the last 52 weekly readings, and has been out of that trend for the last 21 weeks. It is 8.4% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 21
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$18.1M
Insider sales, 12 months
$272K
Officials’ trades on record
6
Institutions holding
182 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 18 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$48.8M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

6 disclosed lines: House 6, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
James B. Renacci House: U.S. House ClerkOH16sold$1k–$15k15 Dec 2017filed 21 Dec 2017
James B. Renacci House: U.S. House ClerkOH16bought$1k–$15k13 Jan 2017filed 24 Jan 2017
James B. Renacci House: U.S. House ClerkOH16sold$1k–$15k13 Dec 2016filed 20 Dec 2016
James B. Renacci House: U.S. House ClerkOH16bought$1k–$15k17 Nov 2016filed 6 Dec 2016
James B. Renacci House: U.S. House ClerkOH16bought$1k–$15k1 Jul 2015filed 22 Jul 2015
James B. Renacci House: U.S. House ClerkOH16bought$1k–$15k1 Jul 2015filed 22 Jul 2015

Insiders

Buy orders, 12 months16
Sale orders, 12 months2
Buyers · sellers1 · 2
WhoDidSharesTraded
William P. Scully10% ownerbought10,000at $8.4614 Oct 2026filed 15 Oct 2026
William P. Scully10% ownerbought100,000at $8.3513 Oct 2026filed 15 Oct 2026
William P. Scully10% ownerbought90,000at $8.578 Oct 2026filed 9 Oct 2026
William P. Scully10% ownerbought125,000at $8.407 Oct 2026filed 9 Oct 2026
William P. Scully10% ownerbought100,000at $8.572 Oct 2026filed 6 Oct 2026
William P. Scully10% ownerbought162,000at $8.6829 Sep 2026filed 30 Sep 2026
William P. Scully10% ownerbought103,500at $8.6028 Sep 2026filed 29 Sep 2026
William P. Scully10% ownerbought100,000at $8.4318 Sep 2026filed 21 Sep 2026
William P. Scully10% ownerbought27,000at $9.472 Sep 2026filed 3 Sep 2026
William P. Scully10% ownerbought50,000at $8.7920 Aug 2026filed 21 Aug 2026
William P. Scully10% ownerbought34,000at $8.627 Aug 2026filed 10 Aug 2026
William P. Scully10% ownerbought3,500at $8.627 Aug 2026filed 10 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders182+6 on the quarter
New · exited29 · 23
Reported value$445.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FMR LLCreduced · filed 13 Aug 20267,199,218$70.5M-352,000−4.7%
Rubric Capital Management LPunchanged · filed 14 Aug 20265,000,000$49.0M00.0%
BlackRock, Inc.added · filed 7 Aug 20264,867,955$47.7M+223,795+4.8%
STATE STREET CORPadded · filed 7 Aug 20262,393,424$23.4M+454,926+23.5%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20261,651,293$16.2M+205,314+14.2%
D. E. Shaw & Co., Inc.reduced · filed 14 Aug 20261,611,457$15.8M-151,890−8.6%
ADAR1 Capital Management, LLCreduced · filed 14 Aug 20261,554,535$15.2M-26,908−1.7%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 20261,264,987$12.4M+59,009+4.9%
Palo Alto Investors LPreduced · filed 17 Aug 20261,143,155$11.2M-65,413−5.4%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,125,877$11.0M+27,711+2.5%
31 Mar 2023 – 30 Jun 2026
143162181Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

William P. Scully Company insider10% owner · last 14 Oct 202620 · 0
Anne Evans Kingston Company insiderChief Strategy Officer · last 29 Jul 20260 · 1
Michael John Isaacs Company insiderGeneral Counsel & Company Sec. · last 29 Jul 20260 · 1
Brandon S. Smith Company insiderChief Operating Officer · last 28 Jul 20260 · 5
Chad J. Swanson Company insiderChief Development Officer · last 28 Jul 20260 · 0
Gene G. Kinney Company insiderPresident and CEO · last 28 Jul 20261 · 17
Karin L. Walker Company insiderChief Accounting Officer · last 28 Jul 20260 · 30
Tran Nguyen Company insiderChief Strategy Officer and CFO · last 28 Jul 20262 · 13
Wagner M. Zago Company insiderChief Scientific Officer · last 28 Jul 20260 · 7
Daniel G. Welch Company insiderDirector · last 15 May 20260 · 0
Dennis J. Selkoe Company insiderDirector · last 15 May 20260 · 18
Lars Ekman Company insiderDirector · last 15 May 20260 · 6

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-75.1%
Interest coverFY 2025 · to 31 Dec 2025-15.18×
Share count trendFY 2025 · to 20 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$307.5M

Analyst forecasts

No analyst forecasts yet.